Key takeaways
- Soluble fiber has the strongest LDL-lowering evidence: a meta-analysis of 181 RCTs found each 5 g/day increment reduced LDL-C by 8.28 mg/dL and total cholesterol by 10.82 mg/dL, with the review authors reporting no funding.
- Plant sterols/stanols reliably lower LDL-C (a 59-trial meta-analysis found a 0.31 mmol/L reduction), but a key older meta-analysis disclosed an author consulting for Danone, Unilever, and other sterol-product makers — useful evidence, but downgraded for conflicts and lack of hard-event trials.
- Cochrane found long-chain omega-3 (EPA/DHA) has little or no effect on all-cause mortality or cardiovascular events overall, though it still lowers triglycerides — a clear case where a popular supplement helps a marker but not proven hard outcomes.
- Magnesium's blood-pressure effect is real but small: 34 double-blind placebo-controlled trials found a median 368 mg/day for 3 months reduced systolic BP by just 2.00 mmHg and diastolic BP by 1.78 mmHg.
- NCCIH states detox/cleanse studies are low quality with no compelling evidence for toxin elimination, and a review of homeopathy reviews found no strong evidence it outperforms placebo for any condition — both categories risk delaying proven cardiac care.
The best heart-related supplement evidence is narrow: soluble fiber and plant sterols lower LDL cholesterol; omega-3 EPA/DHA lowers triglycerides but has mixed event-prevention evidence; magnesium can modestly lower blood pressure in some adults; CoQ10 may be a clinician-supervised adjunct in selected heart-failure patients; garlic and folate show limited, context-specific risk-marker or stroke evidence (
soluble fiber meta-analysis,
plant sterol meta-analysis,
Cochrane omega-3 review). Popular “heart cleanses,” homeopathic heart drops, chelation-style supplement kits, miracle cholesterol blends, and detox programs do not have convincing independent evidence as heart-disease treatments and may delay proven care (
NCCIH detoxes and cleanses,
homeopathy systematic-review review).
Table of contents
Evidence summary
| Ingredient / claim | Evidence | Funding / conflict trace | Pure City verdict |
|---|
| Soluble fiber lowers LDL-C. | 181 RCTs found each 5 g/day increment of soluble fiber reduced LDL-C by 8.28 mg/dL, total cholesterol by 10.82 mg/dL, triglycerides by 5.55 mg/dL, and apoB by 44.99 mg/L (soluble fiber meta-analysis). | Authors reported no funding for the review. | Works for LDL marker |
| Psyllium lowers LDL-C. | A 28-trial meta-analysis found psyllium reduced LDL-C and non-HDL-C, with GRADE assessment performed (psyllium meta-analysis). | Funding not shown in PubMed excerpt; individual psyllium trials may be brand-linked. | Works for LDL marker |
| Plant sterols/stanols lower LDL-C. | A 59-trial meta-analysis found plant sterol products decreased LDL-C by 0.31 mmol/L; a 124-study dose analysis found LDL-C reductions across 0.6–3.3 g/day intake ranges (plant sterol meta-analysis, plant sterol dose-response meta-analysis). | Older meta-analysis disclosed one author consulting for Danone, Unilever, Forbes Meditech, Whitewave, and Enzymotec; evidence is credible for LDL but downgraded for conflicts and lack of event trials. | Works for LDL marker |
| Omega-3 EPA/DHA prevents cardiovascular events in general users. | Cochrane found little or no effect of increased long-chain omega-3 on all-cause mortality or cardiovascular events overall (Cochrane omega-3 review). | Cochrane is nonprofit evidence synthesis; many individual omega-3 product trials are industry-supported and conflict-sensitive. | Mixed; works better for triglycerides |
| CoQ10 improves heart failure outcomes. | Cochrane found possible benefits in heart failure but noted evidence limitations; NCCIH describes heart-failure results as inconclusive overall (Cochrane CoQ10 review, NCCIH CoQ10). | Several influential heart-failure trials were product-linked; use only as adjunct evidence. | Maybe, clinician-led adjunct |
| Magnesium lowers blood pressure. | 34 double-blind placebo-controlled trials found median 368 mg/day for 3 months reduced systolic BP by 2.00 mmHg and diastolic BP by 1.78 mmHg (magnesium BP meta-analysis). | No supplement-company funding shown in PubMed excerpt; NIH ODS safety reference is government-funded. | Small effect |
| Garlic improves cardiovascular risk factors. | A 2025 meta-analysis of 108 RCTs reported improvements in serum lipids and other risk factors, but NCCIH notes garlic BP evidence is not strong because studies are often small or lower quality (garlic RCT meta-analysis, NCCIH hypertension digest). | Meta-analysis lists Kerman University of Medical Sciences funding; NCCIH is government evidence digest. | Modest / mixed |
| Folate prevents heart disease. | Folic acid lowers stroke risk more consistently than coronary heart disease risk; NIH ODS says folic acid/B12 lower homocysteine but do not clearly reduce overall CVD risk aside from stroke signals (NIH ODS folate, folic acid CVD meta-analysis). | Benefits depend on baseline folate status; this article avoids country-specific fortification claims. | Context-specific |
| Detoxes, cleanses, and homeopathic heart remedies treat heart disease. | NCCIH says detox/cleanse studies are low quality and no compelling evidence supports detox diets for toxin elimination; systematic reviews fail to provide strong evidence that homeopathy works better than placebo for any condition (NCCIH detoxes and cleanses, homeopathy review of reviews). | Detox evidence is often commercial/marketing-driven; homeopathy review author disclosed being a trained homeopath but no financial interest. | Do not rely |
Evidence ladder for heart supplementsHard outcomes outrank lab markers; independent reviews outrank marketing.StrongestCochrane or independent meta-analysis showing heart events or mortality.UsefulConsistent LDL, triglyceride, BP, or stroke-marker effects with safety checks.WeakSmall trials, surrogate-only claims, or product-specific funding.Do not relyDetox, homeopathy, and miracle-cure claims without credible clinical evidence.
Text version of infographic: Evidence ladder for heart supplements
| Item | Meaning |
|---|
| Strongest | Systematic reviews showing fewer clinical events or lower mortality are highest value. |
| Useful | LDL, triglyceride, BP, and stroke risk-marker benefits can matter when matched to the person. |
| Weak | Small product-funded studies or surrogate-only claims need downgrading. |
| Do not rely | Detoxes, homeopathy, and miracle-cure claims should not replace medical care. |
| Ingredient | Common forms | Best-supported form/use | Evidence caveat |
|---|
| Omega-3 | Fish oil, krill oil, cod liver oil, algal EPA/DHA, purified EPA, mixed EPA+DHA, flax/chia ALA. | EPA/DHA for triglycerides; ALA is not equivalent because conversion to EPA/DHA is limited (NIH ODS omega-3). | Event-prevention claims depend on dose, form, population, background therapy, and trial funding. |
| CoQ10 | Ubiquinone, ubiquinol, oil-solubilized capsules, powders, gummies, enhanced-delivery formulas. | Absorbed better with fat-containing meals; adjunct heart-failure evidence is not form-proof across brands (NCCIH CoQ10). | Formulation studies are often product-linked. |
| Magnesium | Citrate, glycinate/bisglycinate, oxide, chloride, lactate, malate, taurate, threonate, sulfate, hydroxide. | Correct deficiency; citrate/glycinate often better tolerated than oxide for repletion, while laxative salts act differently (NIH ODS magnesium). | Heart-specific BP effect is modest; avoid unsupervised use in kidney disease. |
| Soluble fiber | Psyllium husk, beta-glucan from oats/barley, glucomannan, guar gum, pectin, inulin/resistant dextrin blends. | Gel-forming viscous fibers such as psyllium and beta-glucan have stronger lipid evidence than generic “fiber blends” (soluble fiber meta-analysis). | Must be taken with enough fluid and separated from some medicines. |
| Plant sterols/stanols | Free sterols, sterol esters, stanols, stanol esters, fortified foods, capsules, powders. | LDL-C lowering through reduced cholesterol absorption; sterols and stanols both work (plant sterol dose-response meta-analysis). | Hard heart-event trials are lacking; avoid in sitosterolemia (plant sterol review). |
| Garlic | Garlic powder, aged garlic extract, garlic oil, raw garlic, deodorized preparations. | Risk-factor evidence is mixed and form-specific; safety concerns are strongest around bleeding and surgery (NCCIH garlic). | Do not assume culinary garlic effects equal concentrated supplement effects. |
| Folate | Folic acid, folinic acid, L-5-MTHF, food folate. | Folic acid has the largest cardiovascular/stroke trial evidence base; B12 status and medicines matter (NIH ODS folate). | Stroke evidence is context-specific; coronary prevention is not convincing. |
Supplements with useful evidence
Soluble fiber: the most practical LDL-support add-on
Soluble fiber is one of the clearest supplement-style options because it has a plausible gut mechanism, many RCTs, and measurable LDL-C effects. The 181-RCT meta-analysis found lipid improvements per 5 g/day increment, while psyllium-specific evidence supports reductions in LDL-C and non-HDL-C (
soluble fiber meta-analysis,
psyllium meta-analysis).
Practical verdict: soluble fiber works for LDL-C support, but it should be introduced slowly, taken with fluid, and separated from narrow-therapeutic-index medicines. It is best treated as a diet tool, not as a substitute for lipid-lowering therapy in high-risk patients.
Plant sterols and stanols: LDL lowering without event proof
Plant sterols and stanols reduce intestinal cholesterol absorption, and meta-analyses consistently show LDL-C reductions. The key limitation is that no randomized placebo-controlled trials show fewer heart attacks or strokes from phytosterol supplementation itself, so the claim should remain “LDL lowering,” not “proven heart-attack prevention” (
plant sterol meta-analysis,
plant sterol review).
Omega-3: strong for triglycerides, mixed for prevention
Omega-3 is a classic example of form and dose mattering. NIH ODS notes that omega-3 trial findings vary by form, population, background diet, statin use, and dose; Cochrane found little or no overall cardiovascular-event benefit for increased omega-3 intake in long-term RCTs (
NIH ODS omega-3,
Cochrane omega-3 review).
CoQ10: possible adjunct, not core heart therapy
CoQ10 participates in mitochondrial electron transport and is biologically plausible in heart failure, but evidence is not strong enough to make it a replacement for guideline-directed care. Cochrane’s review found possible benefits, while NCCIH describes heart-failure evidence as inconclusive and statin muscle-pain evidence as not supportive overall (
Cochrane CoQ10 review,
NCCIH CoQ10).
Magnesium: useful if low, modest for blood pressure
Magnesium supplementation modestly lowered BP in double-blind RCTs, but the average effect was small. NIH ODS lists diarrhea, nausea, cramping, and medication interactions, and warns that very high magnesium from supplements or medicines can cause toxicity, especially when kidney function is impaired (
magnesium BP meta-analysis,
NIH ODS magnesium).
Garlic and folate: limited, context-specific
Garlic has mixed but plausible risk-marker evidence and a meaningful bleeding-interaction profile. Folate lowers homocysteine and appears more useful for stroke prevention than coronary heart disease prevention, especially when baseline folate status is low, but high supplemental folic acid can complicate B12 deficiency and medication management (
garlic RCT meta-analysis,
NCCIH garlic,
NIH ODS folate).
Ingredient-to-target matchingBuy by target, not by hype.LDL-CSoluble fiber; plant sterols/stanols.TriglyceridesEPA/DHA omega-3 under clinician guidance for high levels.Blood pressureMagnesium has small average reductions; garlic mixed.Heart failure adjunctCoQ10 only as add-on with clinician review.Stroke contextFolate may help when folate status is low; not broad CHD prevention.
Text version of infographic: Ingredient-to-target matching
| Item | Meaning |
|---|
| LDL-C | Soluble fiber and plant sterols/stanols are the best supplement-like LDL marker options. |
| Triglycerides | EPA/DHA omega-3 is most defensible for triglyceride lowering, not universal event prevention. |
| Blood pressure | Magnesium has small average BP effects; garlic evidence is mixed. |
| Heart failure adjunct | CoQ10 belongs in clinician-led add-on discussions, not self-treatment. |
| Stroke context | Folate is context-specific and must account for B12 status and interacting medicines. |
Popular heart supplements with no convincing evidence
| Popular claim | Verdict | Why Pure City downgrades it | Better alternative |
|---|
| “Heart detox” or “artery cleanse” kits | DOESN’T | NCCIH says detox and cleanse studies are low quality and there is no compelling evidence that detox diets eliminate toxins; some products have contained hidden ingredients or false disease-treatment claims (NCCIH detoxes and cleanses). | Measure BP, LDL-C, glucose/A1c, and symptoms; use proven prevention. |
| Homeopathic heart drops | DOESN’T | A systematic review of systematic reviews found no condition or remedy convincingly better than placebo, and the author disclosed being trained in homeopathy but without financial interest (homeopathy review of reviews). | Use evidence-based care; seek urgent help for chest symptoms. |
| “Natural blood thinner” blends | Unsafe claim | Garlic, ginkgo, hawthorn, and many blends can affect bleeding risk, but unpredictable antiplatelet effects are not a safe substitute for prescribed anticoagulation (dietary supplements and bleeding review). | Use prescribed anticoagulants/antiplatelets exactly as directed. |
| Red-flag cholesterol blends with undisclosed actives | INSUFFICIENT / avoid if undisclosed | “Cholesterol support” blends may combine fiber, sterols, garlic, niacin-like compounds, botanicals, or undeclared drug-like ingredients; evidence cannot be judged without exact ingredients and doses. | Choose transparent single-ingredient options with known interactions. |
| Chelation-style oral supplement kits | DOESN’T as self-care | NCCIH describes EDTA chelation for coronary disease as investigational and not something to self-administer; high-dose vitamin/mineral arms did not reduce cardiovascular events in TACT (NCCIH chelation therapy). | Use clinician-directed secondary prevention and rehab. |
| “MTHFR heart cure” methylfolate marketing | Overstated | NIH ODS says folic acid/B vitamins lower homocysteine but do not clearly reduce overall CVD risk, although stroke signals exist; MTHFR claims should not replace measured folate/B12 assessment (NIH ODS folate). | Check folate/B12 status and medicines with a clinician. |
Red flags in heart supplement marketingFour claims that should trigger skepticism.“Cleans arteries”Atherosclerosis is not removed by detox powder.“Replaces statins or blood thinners”Unsafe without clinician approval.“No interactions”False comfort; many supplements interact.“Clinically proven” with no dose or trialEvidence must match ingredient, dose, and outcome.
Text version of infographic: Red flags in heart supplement marketing
| Item | Meaning |
|---|
| Cleans arteries | No detox powder is proven to remove atherosclerotic plaque. |
| Replaces medicines | Supplements should not replace statins, BP medicines, anticoagulants, antiplatelets, or heart-failure medicines without clinician direction. |
| No interactions | Any ingestible can interact; heart patients often use high-risk medicines. |
| Clinically proven | The claim must specify ingredient form, dose, population, trial design, and outcome. |
Risks and all side effects
| Ingredient | Common side effects | Rare but serious side effects | At-risk populations | Independent source |
|---|
| Omega-3 EPA/DHA | Fishy burps, unpleasant taste, nausea, loose stools. | Bleeding caution at high doses; atrial fibrillation signal in some high-dose trials; allergy risk with fish/shellfish-derived products. | Anticoagulant/antiplatelet users, atrial fibrillation history, surgery planning, seafood allergy. | NIH ODS omega-3 |
| CoQ10 | Digestive upset, nausea, diarrhea, appetite loss, insomnia. | Potential warfarin interaction; theoretical oncology-treatment concern. | Warfarin users, oncology patients, pregnancy/lactation due to limited evidence. | NCCIH CoQ10; MSKCC CoQ10 |
| Magnesium | Diarrhea, nausea, abdominal cramping. | Hypermagnesemia with excessive supplemental/medicinal magnesium, especially with impaired renal clearance. | Kidney disease, older adults with reduced kidney function, users of magnesium laxatives/antacids. | NIH ODS magnesium |
| Soluble fiber / psyllium | Gas, bloating, fullness, changes in stool pattern. | Choking or obstruction if not taken with enough liquid; medication absorption changes. | Swallowing difficulty, bowel narrowing/obstruction, multiple medicines. | psyllium meta-analysis; AAFP interaction review |
| Plant sterols/stanols | Mild digestive symptoms; possible carotenoid lowering. | Potential risk in sitosterolemia; long-term hard-outcome safety data are incomplete. | Known/suspected sitosterolemia, children, pregnancy/lactation unless supervised. | plant sterol review |
| Garlic supplements | Breath/body odor, abdominal pain, flatulence, nausea, reflux. | Bleeding risk; allergic reactions; topical raw garlic burns. | Anticoagulant/antiplatelet users, surgery planning, reflux disease, pregnancy/lactation beyond food amounts. | NCCIH garlic |
| Folate / folic acid | Usually well tolerated; occasional GI upset. | Masking B12 deficiency; interactions with methotrexate, antifolate cancer drugs, antiepileptics. | B12 deficiency risk, epilepsy medicines, methotrexate, cancer therapy. | NIH ODS folate |
All interactions
| Ingredient | Interacts with | Mechanism | Severity | Action |
|---|
| Omega-3 | Warfarin, DOACs, aspirin, clopidogrel, surgery | Potential additive bleeding effect, especially with high-dose EPA/DHA. | Use with caution | Disclose use and avoid unsupervised high doses (NIH ODS omega-3). |
| Omega-3 | Atrial fibrillation history | Some high-dose trials reported AF signals. | Monitor / clinician-led | Use clinician-supervised dosing only. |
| CoQ10 | Warfarin | Possible reduction in anticoagulant effect; case reports exist. | Monitor INR | Do not start/stop without INR plan (NCCIH CoQ10). |
| CoQ10 | BP medicines, diabetes medicines | Possible additive BP/glucose effects. | Monitor | Track numbers; clinician adjusts medicines. |
| CoQ10 | Chemotherapy/radiation | Antioxidant activity may affect treatment mechanisms. | Avoid unless approved | Oncology team decides (MSKCC CoQ10). |
| Magnesium | Bisphosphonates; tetracycline and quinolone antibiotics | Mineral chelation reduces drug absorption. | Separate doses | Separate per medicine label/pharmacist guidance (NIH ODS magnesium). |
| Magnesium | Diuretics, PPIs, kidney disease | Diuretics can change magnesium loss; PPIs linked to low magnesium; kidney disease increases toxicity risk. | Monitor / avoid unsupervised | Check labs when indicated (NIH ODS magnesium). |
| Soluble fiber / psyllium | Carbamazepine, lithium, digoxin, thyroid medicines, other oral drugs | Gel can slow or reduce absorption. | Separate doses | Take medicines at a different time; use pharmacist guidance for narrow-therapeutic-index drugs (AAFP interaction review). |
| Plant sterols/stanols | Sitosterolemia; bile acid sequestrants; fat-soluble nutrients | Raises plant sterol burden in sitosterolemia; overlapping gut absorption mechanisms; carotenoid lowering. | Avoid in sitosterolemia; monitor otherwise | Use only if LDL target justifies it and diet includes carotenoid-rich foods (plant sterol review). |
| Garlic | Warfarin, DOACs, aspirin, clopidogrel, NSAIDs, surgery | Antiplatelet and bleeding effects. | Use with caution | Stop before procedures if advised; disclose use (NCCIH garlic, dietary supplements and bleeding review). |
| Garlic | Saquinavir and possibly other drugs | May interfere with drug effectiveness. | Avoid/monitor | Check with pharmacist (NCCIH garlic). |
| Folate | Methotrexate, trimethoprim, pyrimethamine, capecitabine/5-FU-class drugs, antiepileptics, cholestyramine/colestipol, antacids, zinc | Folate antagonism, altered folate absorption/metabolism, possible seizure-medication level changes, B12 masking. | Clinician-led | Do not self-prescribe high-dose folate with these medicines (NIH ODS folate). |
Safety triage before buyingFour questions prevent most supplement mistakes.What target?LDL, TG, BP, deficiency, or symptoms?What dose and form?Evidence must match the actual ingredient.What medicines?Warfarin, antiplatelets, BP, diabetes, thyroid, epilepsy, cancer drugs.What stop rules?Bleeding, palpitations, severe GI symptoms, allergy, or worsening labs.
Text version of infographic: Safety triage before buying
| Item | Meaning |
|---|
| Target | Choose supplements only for a measurable target. |
| Dose/form | Evidence is not transferable across all forms and doses. |
| Medicines | Check interactions with anticoagulants, antiplatelets, BP drugs, diabetes medicines, thyroid medicines, antiepileptics, and cancer drugs. |
| Stop rules | Stop and seek care for bleeding, palpitations, severe GI symptoms, allergy, or worsening labs. |
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|
| Soluble fiber lowers LDL-C. | WORKS | 181 RCT meta-analysis and psyllium meta-analysis. | Separate from some medicines and take with fluid. |
| Plant sterols/stanols lower LDL-C. | WORKS | 59-trial and 124-study meta-analyses. | No hard-outcome trial proof; avoid in sitosterolemia. |
| Omega-3 lowers triglycerides. | WORKS | NIH ODS and clinical trial evidence. | Event prevention is mixed; high-dose use requires clinician review. |
| Omega-3 prevents heart attacks in all adults. | DOESN’T | Cochrane found little/no overall CVD event benefit. | Do not extrapolate from prescription high-dose trials to low-dose OTC capsules. |
| CoQ10 helps selected heart-failure patients. | MIXED / POSSIBLE | Cochrane signals but NCCIH calls evidence inconclusive. | Use only as adjunct; check warfarin and oncology interactions. |
| Magnesium meaningfully treats hypertension alone. | DOESN’T | Average BP reduction about 2/1.8 mmHg. | Helpful if low; unsafe in kidney disease without supervision. |
| Garlic replaces BP or cholesterol medicines. | DOESN’T | Risk-marker evidence mixed and modest. | Bleeding interactions matter. |
| Folate prevents heart attacks. | INSUFFICIENT | Stroke signal stronger than CHD signal. | B12 and interacting medicines matter. |
| Detoxes/cleanses clean arteries. | DOESN’T | NCCIH finds no compelling detox evidence. | May contain hidden ingredients or delay care. |
| Homeopathy treats heart disease. | DOESN’T | Systematic reviews do not support effects beyond placebo. | Dangerous if used for chest pain or diagnosed disease. |
Final verdict matrixUseful does not mean universal.Use first if target matchesSoluble fiber; plant sterols for LDL-C.Use selectivelyOmega-3 for triglycerides; magnesium if low or modest BP goal; CoQ10 in heart-failure discussion.Use cautiouslyGarlic and folate due to interactions and context-specific evidence.Avoid as treatmentDetoxes, cleanses, homeopathy, miracle blends, oral chelation kits.
Text version of infographic: Final verdict matrix
| Item | Meaning |
|---|
| Use first if target matches | Soluble fiber and plant sterols are strongest for LDL-C lowering. |
| Use selectively | Omega-3, magnesium, and CoQ10 require the right indication and safety review. |
| Use cautiously | Garlic and folate can be useful but interactions and context matter. |
| Avoid as treatment | Detoxes, cleanses, homeopathy, miracle blends, and oral chelation kits should not be used as heart disease treatment. |
Frequently asked questions
What is the best supplement for heart disease?
There is no single best supplement for heart disease. If LDL-C is the target, soluble fiber or plant sterols/stanols have the clearest marker evidence; if triglycerides are high, EPA/DHA omega-3 is more relevant; if deficiency is present, magnesium or folate may be relevant under supervision (soluble fiber meta-analysis, NIH ODS omega-3).
Does fish oil prevent heart attacks?
Not as a blanket claim. Cochrane found little or no overall effect of increased long-chain omega-3 on cardiovascular events, while some high-dose purified EPA evidence differs by population and product; that makes fish oil a targeted triglyceride or clinician-led adjunct discussion, not universal heart insurance (Cochrane omega-3 review, NIH ODS omega-3).
Can CoQ10 be taken with statins?
CoQ10 is often marketed for statin muscle symptoms, but NCCIH says overall evidence does not support CoQ10 for statin-related muscle pain. CoQ10 can interact with warfarin and may affect blood pressure or glucose, so statin users with multiple medicines should still review it with a clinician or pharmacist (NCCIH CoQ10).
Are plant sterols safer than statins?
That comparison is misleading because plant sterols lower LDL-C modestly but have no randomized hard-outcome evidence proving fewer heart attacks or strokes, while statins have large hard-outcome trial meta-analyses. Plant sterols also require caution in sitosterolemia and may lower carotenoid levels (plant sterol review, CTT meta-analysis).
Is garlic safe for the heart?
Food-level garlic is different from concentrated garlic supplements. NCCIH lists breath/body odor, abdominal pain, flatulence, nausea, allergy, topical burns from raw garlic, and increased bleeding risk with anticoagulants or aspirin-like medicines (NCCIH garlic).
Should folate be used for MTHFR and heart disease?
Folate decisions should be based on measured status, diet, pregnancy-related needs when relevant, B12 status, and medicines, not genetic marketing alone. NIH ODS says folic acid/B vitamins lower homocysteine but do not clearly lower overall cardiovascular disease risk, although stroke reduction signals are stronger (NIH ODS folate).
Are detoxes or cleanses useful for heart disease?
No credible evidence supports detoxes or cleanses as heart-disease treatment. NCCIH reports low-quality detox studies and no compelling evidence for toxin elimination, and some products have been targeted for hidden ingredients or false serious-disease claims (NCCIH detoxes and cleanses).
Sources and funding notes
| Source | URL | Funding / conflict note |
|---|
| Soluble fiber meta-analysis | PMC10201678 | Authors reported no funding. |
| Psyllium meta-analysis | PubMed 30239559 | Funding not shown in PubMed excerpt; individual trials may be product-linked. |
| Plant sterol meta-analysis | PMC2596710 | One author disclosed consulting ties to food/ingredient companies; LDL evidence downgraded for conflict sensitivity. |
| Omega-3 Cochrane review | Cochrane CD003177 | Cochrane evidence synthesis; individual omega-3 trials may have product sponsorship. |
| CoQ10 Cochrane review | PMC8092430 | Review methods strong; included trials varied, and influential CoQ10 trials had industry ties. |
| Magnesium BP meta-analysis | PubMed 27402922 | No supplement-company funding shown in PubMed excerpt. |
| Garlic safety | NCCIH garlic | Government evidence and safety reference. |
| Folate safety | NIH ODS folate | Government nutrient reference. |
| Detoxes and cleanses | NCCIH detoxes and cleanses | Government complementary-health evidence reference. |
| Homeopathy review of reviews | PMC1874503 | Author disclosed being a trained homeopath and no financial interest; conclusions still negative. |
